ENVB Latest News, Press Relases and Analysis

All

Press Releases

11 days ago - By: Enveric Biosciences

Enveric Biosciences Announces Reverse Stock Split

18 days ago - By: Enveric Biosciences

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

19 days ago - By: Enveric Biosciences

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

20 days ago - By: Enveric Biosciences

Enveric Biosciences to Explore Digital Asset Treasury Opportunities

a month ago - By: Enveric Biosciences

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

a month ago - By: Benzinga - Mentions: NBY NEOG PMI APDN ...

12 Health Care Stocks Moving In Monday's After-Market Session

2 months ago - By: Enveric Biosciences, Inc.

Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

2 months ago - By: Benzinga - Mentions: USBC CURX CODX SPRC ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

2 months ago - By: Enveric Biosciences, Inc.

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

2 months ago - By: Enveric Biosciences

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

2 months ago - By: Enveric Biosciences

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

2 months ago - By: Enveric Biosciences

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

2 months ago - By: Enveric Biosciences

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

2 months ago - By: Enveric Biosciences, Inc.

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

3 months ago - By: Enveric Biosciences

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

3 months ago - By: Enveric Biosciences

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

4 months ago - By: Enveric Biosciences

Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

4 months ago - By: Enveric Biosciences

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

5 months ago - By: Enveric Biosciences

Enveric Biosciences Announces Participation in 2025 BIO International Convention

5 months ago - By: Enveric Biosciences

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

5 months ago - By: Enveric Biosciences

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

5 months ago - By: Enveric Biosciences

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

6 months ago - By: Enveric Biosciences

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

6 months ago - By: Enveric Biosciences

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

7 months ago - By: Enveric Biosciences

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

8 months ago - By: Enveric Biosciences, Inc.

Enveric Biosciences Participating in BIO-Europe Spring®

8 months ago - By: Enveric Biosciences

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

8 months ago - By: Enveric Biosciences

ENVERIC BIOSCIENCES INC (ENVB) Stock News

ENVB Latest News, Press Relases and Analysis

Enveric Biosciences Announces Reverse Stock Split

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Enveric Biosciences to Explore Digital Asset Treasury Opportunities

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

12 Health Care Stocks Moving In Monday's After-Market Session

Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

12 Health Care Stocks Moving In Wednesday's Intraday Session

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

Enveric Biosciences Announces Participation in 2025 BIO International Convention

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

Enveric Biosciences Participating in BIO-Europe Spring®

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

Enveric Biosciences CEO Issues Letter to Shareholders